Introduction
There is evidence that insulin-dependent diabetes mellitus (IDDM)' is a chronic autoimmune disease in which the pres-ence ofautoantibodies, such as cytoplasmic islet cell antibodies or insulin autoantibodies, can be present years before the clinical onset of the disease (1) . A common feature of type I diabetes and other autoimmune diseases is a humoral immune response characterized by the appearance of autoantibodies against cellular proteins, including islet peptides (2) (3) (4) . Although all the target antigens in type I diabetes have not been identified, several autoantigens associated with the disease have been molecularly characterized using different experimental approaches, namely insulin (5), glutamic acid decarboxylase (GAD) (6) , carboxypeptidase H (7), as well as the glycolipids GT3 (8) and GM2-1 (9) . Recently, cDNA encoding for a fragment of carboxypeptidase H (7), a granule-associated enzyme, has been reported to react with sera from prediabetic patients and another peptide expressed in a Xgt 11 phage from a human islet library appears to be recognized by IDDM sera ( 10) . Cellular proteins of unknown sequence whose molecular masses are 38 (11), 52 (12) , and 69 kD ( 13) , have also been reported to be recognized by a humoral and/or a cellular immune response. It is of interest that almost all patients with type I diabetes have elevated levels of IgG anti-BSA antibodies related to a 69,000-Mr islet peptide, which may represent a target antigen for cow milk-induced islet autoimmunity (14, 15) .
The present study was undertaken to isolate clones that code for some of these or other unidentified autoantigens and characterize their molecular structure. Isolation of cDNA clones expressing antigenic determinants has been extensively used to identify clones coding for autoantigens in different autoimmune diseases ( 16) . This approach offers the possibility of identifying and characterizing novel autoantigens that may be of restricted cellular distribution as well as low cellular expression (17) . Such proteins may not be detected by routine screening tests such as immunofluorescence or immunoprecipitation.
We have used this approach to immunoscreen a human islet Xgtl 1 expression library with a pool of sera from prediabetic relatives ofIDDM patients, identify, sequence the clones, and characterize the expressed proteins. In this report, we describe the cloning ofa cDNA that encodes a novel islet autoantigen, whose apparent migration is 69 kD on SDS-polyacrylamide gel chromatography.
Methods
Serum samples. Sera were obtained from first degree relatives of patients with type I diabetes. All of them were at high risk of developing IDDM, and some have already progressed to the overt disease on prospective follow-up. Clinical studies were performed with informed consent, as well as approval from the Joslin Clinic and University ofColorado institutional review boards. All the sera used for the screening of the human islet Xgt 1I library expressed high titer ofislet cell antibodies (> 80 Juvenile Diabetes Foundation units). The sera were repeatedly absorbed with a protein lysate of a wild Xgtl 1 phage-infected Esche-richia coli strain Y1090 (18) to remove anti-E. coli antibodies. Absorbed antibodies were stored at -20'C in the presence of 0.05% sodium azide until used for immunological screening. Originally, a pool ofthree sera was used to identify positive clones, and subsequently sera of three other relatives were studied for reactivity with the positive clone. 10 sera of normal individuals were also tested for reactivity with the positive clone. Sera from additional prediabetic relatives (subjects followed to diabetes onset) (n = 23), autoantibody positive but currently nondiabetic relatives (n = 31 ), and normal controls (n = 70) were tested for reactivity to the expressed molecule on Western blots.
XgtJ 1 expression libraries. Two Xgt 11 libraries were used, a human islet library provided by Dr. Alan Permutt (Washington University, St. Louis, MO) and a human insulinoma library generated by Alvin C. Powers (Vanderbilt University, Nashville, TN). A human Xgtl 1 islet library was constructed from human islet poly(A') mRNA by Clontech (Palo Alto, CA), with I x 09 plaque-forming units (pfu)/ml and 85% being recombinants. A human insulinoma library was generated from insulinoma poly(A+) mRNA and then cDNA was produced and packaged into the Xgtl 1 phage ( 19) , with -1.3 x I09 pfu/ ml and a recombinant rate of more than 80%.
Screening of Xgtl I expression libraries with antibody and cDNA probes. A phage human islet Xgtl 1 expression library was screened with a pool of sera from preclinical IDDM relatives (20) . Isolated recombinant phages were plated on Luria-Bertani (LB) agar plates ( 150 mm diameter) with E. coli strain Y1090 at 0.5-1 X 104 pfu/plate. After a 3-h incubation at 42°C, a nitrocellulose filter (Schleicher & Schuell, Keene, NH) saturated with 10 mM isopropyl-#-D-thiogalactopyranoside (IPTG) (BRL, Grand Island, NY) was overlaid on the agar overnight at 37°C to induce the expression of f-galactosidase fusion proteins. After that, the filters were blocked with 1% BSA (Sigma Immunochemicals, St Louis, MO) in Tris-buffered saline (TBS), incubated containing 0.05% Tween, incubated for 2 h at room temperature), and then incubated with 1/500 diluted sera overnight at 4°C. After several washes with TBS, the bound antibodies were detected by incubation with anti-human IgG alkaline phosphatase (Cappel Laboratories, Durham, NC) diluted 1/ 100 (2 h at room temperature). A phage human islet XgtlI expression library was initially screened with pooled sera from three prediabetics. The original positive plaque was replated and rescreened sequentially until all progeny of plaques were recognized by the sera. To determine whether prediabetic sera or controls reacted with the product of the clone and to reduce the possibilities of false positivity, plaque-purified recombinant bacteriophage was mixed -1:1 with a wild-type Xgtl 1 and plated with E. coli Y1090 as for screening. Pieces of nitrocellulose carrying plaque proteins were then incubated with individual sera. Reactions were considered positive if significant staining of -50% ofthe plaques was observed. Intensity of staining was estimated to score reactivity of individual sera on a 0 (negative) to 4+ (strongest) scale. The cDNA insert of the original positive clone, termed PMI / 1 (Fig. I B) , was used as probe to further screen the human islet library and a human insulinoma library by plaque hybridization (21 ) agarose gel stained with ethidium bromide to visualize the PCR products, the product of interest was excised, purified, and subcloned into the Eco RI site of pBluescript II vector. This vector was used to transform E. Coli strain XLl Blue, and to sequence the PCR products across its polylinker arms (Stratagene, La Jolla, CA). cDNA samples for PCR were obtained from phage suspension.
DNA sequencing and computer analysis ofnucleic acid and protein sequences. Nucleotide sequences were determined by usingthe dideoxynucleotide chain termination method of Sanger et al. (25) , using T7 DNA polymerase (Sequenase; United States Biochemical Corp., Cleveland, OH). To avoid compression in G + C-rich sequences, additional sequencing reactions were performed with dITP alternating with dGTP (26) .
Sequences were aligned and analyzed using the EUGENE, SAM, PIMA.SH, and PROSITE programs. The GenBank (DNA and Amino Acid Databank) was searched for similarities, and the PLSEARCH program analyzed for protein sequence patterns derived from the sequences of homologous protein families (Molecular Biology Computing Research Resource, Dana Farber Cancer Institute, and Harvard School of Public Health, Cambridge, MA). Hydropathy plots from the deduced amino acid sequence were prepared as described by Kyte and Doolittle (27, 28) and Klein et al. (29) .
Cell lines. Cells were used at late log phase, when almost all were viable. RIN 1046-38, derived from a rat insulinoma (kindly provided by Christopher Newgard, Southwestern Medical Center, University of Texas, Dallas, TX), were cultured in DME supplemented with 10% FBS, and 5.6 mM glucose in a humidified atmosphere of 10% C02/ 90% air at 370C (30) . flTC-I and aTC-I were derived from progeny of transgenic mice expressing SV40 large T-antigen under control of the rat insulin II 5'-flanking region or rat preproglucagon 5'-flanking region respectively (31) (32) (33) . The FTC-I and aTC-6 cell lines were maintained in DME supplemented to a final concentration of 16 (47) and preimmune sera from normal rabbits were used in each assay as positive and negative controls respectively. The optical density of the solutions in the wells was measured with a spectrophotometer through a 405-nm filter.
SDS-PAGE and immunoblotting. Cell line extracts and total homogenates of rat brain tissues were prepared as described by Laemmli (48) . Cell line extracts and total-homogenate proteins were separated by SDS-PAGE using a constant voltage of 180 V for 4 (49) in transfer buffer (12.5 mM Tris, 96 mM glycine, 20% methanol) for 1 h on a semi-dry electrophoretic transfer cell at 15 V. The nitrocellulose was cut into strips, and incubated for 2 h at 37°C in 5% (wt/vol) nonfat dried milk diluted in PBS (Blotto buffer) to block the nonspecific binding sites. The nitrocellulose strips were then incubated with a 1: 100 dilution of a rabbit anti-ICA69 antiserum and then washed in 5% (wt/vol) nonfat dried milk diluted in PBS adding Tween 20 to a final concentration of 0.01%. After incubation of the filters at room temperature for 2 h with '251-Protein A (Amersham Corp.) to detect the rabbit anti-ICA69 antibodies, unbound 1251-Protein A was removed by washing as described above. Blots were exposed to Kodak film at -80°C with intensifying screens for 12-24 h.
Expression of the recombinant ICA69. PM 1/3 clone cDNA was amplified by PCR. The PCR product was generated using a primer spanning the PM 1/3 start codon and encoding the first eight amino acids (5'-TCAGGACACAAATGCAGTTATCCC-3'), and a primer containing the codon sequence for the last seven amino acids, a translational stop codon and a HindIII restriction site ( 5'-TTTAAGCTTTCA-TGCATTGAGCAATTCGTGTTC-3'). The pMAL-c vector (50, 51 ) , which encodes for maltose binding protein as product of the malE gene, was cut with StuI and HindIII restriction enzymes and ligated with the PM 1/ 3 PCR product. The constructs were then transfected into the appropriate E. coli, strain TB I ( 52 ) . Ampicillin-resistant colonies were grown overnight in 3 ml LB medium containing 100 jIg/ml ampicillin. 100 jil of TBI pMAL-c-PMI /3 transformants were diluted in 1 ml LB/ampicillin medium and grown 1 h at 370C followed by induction with 1 mM IPTG for 2 h. Lysates were prepared by centrifugation of 200 il bacterial cultures for 1 min and boiling the cell pellet with 50 jl SDS sample buffer with 5% mercaptoethanol. After SDS-PAGE of lysates (10 Al) with and without IPTG induction, gels were stained with Coomassie blue. One colony expressing a protein whose molecular mass migrated -105 kD was identified, and the correct size of the insert was confirmed by restriction analysis.
Another vector system was used to express the purified recombinant ICA69 protein without maltose binding protein. The coding region of the PM 1/3 cDNA clone, was amplified by PCR using the primers 5'-GAAGGATCCATGTCAGGACACAAATGCAG-3' and 5'-GGTCTCGAGTCATGCATTGAGCAATTCGTG-3' and cloned into the BamHI and XhoI sites of the expression vector pTrc99A(His6). This vector was constructed by insertion ofa synthetic DNA fragment encoding six histidines ([CAC]6) into the polylinker of pTrc 99A (53). Recombinant proteins were tagged with six histidine residues at the NH2 terminus. The plasmid construct was transformed into E. coli-Tgl and protein expression was induced by the addition of IPTG to the culture medium. After 2 h at 37°C, bacteria were lysed in 100 mM Tris pH 8.0, 6 M GuHCl, and 10 mM DTT, and insoluble material was removed by centrifugation at 40,000 g for 30 min. Recombinant (His)6-ICA69 was purified using Ni-NTA-agarose (Qiagen, Chatsworth, CA) in the presence of 6 M GuHCl, 1 mM DTT buffer. The correct size of the ICA69 cDNA in the vector was confirmed by sequencing.
Lysates containing ICA69 and maltose binding protein fusion protein, as well as the purified recombinant ICA69, have been used as source for performing Western blots with control sera such as rabbit anti-ICA69 sera (pre-and postimmune), human control sera, and prediabetic sera at a dilution 1:100. Optical density of the bands corresponding to the ICA69 fusion protein and the affinity-purified ICA69 has been evaluated to quantitate the reactivity ofthe serum samples to ICA69 using a video densitometer (Bio Rad Laboratories, Hercules, CA), and the results were expressed as relative densitometric units.
Immunohistochemistry. Immunohistochemistry has been performed in formalin fixed rat pancreas paraffin embedded sections (4 Am thickness). A double immunoenzymatic labeling of rat islet cellular constituents has been performed (54, 55) using as detection system horseradish peroxidase antiperoxidase (PAP) and alkaline phosphatase-antialkaline phosphatase (APAAP). The PAP immune complex served for the identification of ICA69, whereas the APAAP complex for the identification of insulin, glucagon and somatostatin. After removal of paraffin and rehydratation of tissue, the pancreas sections were first treated with an hydrogen peroxidase solution to suppress possible endogenous peroxidase activity. This was followed by an incubation with normal serum to quench nonspecific protein binding to certain tissue elements, and then the sections were incubated with a primary antibody mixture (rabbit anti-ICA69 antibody generated to the whole molecule, and a mouse mAb generated insulin subjects' sera (individually tested at 1:500 dilutions of the sera), whereas no reaction was obtained with 10 control individual sera. A labeled cDNA probe derived from the PM 1/1 clone was used to screen both a human Xgt 11 islet library and a human insulinoma Xgtl 1 library to obtain the full-length cDNA. Screening -6.5 x 104 pfu, two additional hybridizing and overlapping clones were identified from the human islet Xgt 11 expression library, both of which retained specificity after secondary and tertiary screening to 100% purity. DNA sequence analysis (see below) confirmed that the clones contained fragments of the same gene.
DNA sequence. After PCR amplification and subcloning into pBluescript II vector, partial sequence indicates that the smallest overlapping clone (PM 1/2), whose size is 0.6 kb, reveals sequence totally contained within the original sequenced PM 1/ 1 insert (Fig. 1 B) . The results of sequencing both cDNA strands of the longest clone (PM 1/3), whose size is 1.78 kb, indicates complete identity in the region of the molecule overlapping with the two clones and sequence not contained within the previous clones.
Analysis ofthe Kozak (61 ) . Upstream from the first ATG, there is an in frame stop codon (TAA) at -75 bp (Fig. 1 A) . The predicted open reading frame from the deduced ATG start codon, codes for a protein with an estimated linear relative molecular mass of 54,600, which contains one potential N-linked glycosylation site.
Using computer programs to search databases of known nucleic acid or amino acid sequences, no significant similarities were found except for minimal homology with BSA, implying that our sequence was new and unique. Two short regions of bovine but not human serum albumin precursor appear to have similarities with the ICA69 molecule (Fig. 2) .
A hydrophobicity plot generated from the ICA69 inferred amino acid sequence reveals a number of slightly hydrophobic regions, alternating with several very hydrophilic segments, which suggests that the molecule does not contain any membrane spanning domain, according to the criteria defined by both Kyte and Doolittle (27, 28) and Klein et al. (29) . The segments of hydrophobicity appear not to be long enough to be potential transmembrane-spanning regions. The molecule is predominantly hydrophilic, with 27% of its amino acid residues positively or negatively charged.
Analysis of ICA69 transcripts in normal and tumor cells. The cDNA derived from two clones (PM 1/1, PM 1/ 3) was used to probe for transcripts in human and animal tissues and in several cell lines by Northern analysis (Figs. 3 and 4) . Probes consisting of 0.95 kb (PM 1/ 1 ) and 1.78 kb (PM 1/3 ) hybridized with a 2-kb mRNA band in islet-derived cell lines, and in some tissues, with a 2.7-kb band. Fig. 3 shows a Northern blot of ICA69 transcripts in human tissues. A 2-kb poly(A+) RNA band was detected in abundant amounts in both human pancreas and heart, and then in brain, and in small amounts in lung, liver and kidney, but not in placenta and skeletal muscle. In brain and heart, an additional 2.7-kb band is visible. A 2-kb poly( A') RNA band was also detected in human thyroid, but not in ovary and spleen (not shown). The /3-actin control probe hybridized with a 2-kb band in all tissues with different intensity, and with a smaller band ( 1.6 kb) in both heart and IC 69 N The blot was exposed for 4 h (j3-actin cDNA probe) and 24 h (PM / 1 cDNA probe) at -80°C with intensifying screen. skeletal muscle. This is because ,B-actin is not expressed in equal amount in all tissues and because there are two forms of f3-actin mRNA in both heart and skeletal muscle (2 and 1.6 kb) (40) . The labeled cDNA PM 1/ 1 insert hybridizes with a 2-kb mRNA band in total RNA from rat pancreas, brain, and cerebellum and kidney (in the last three tissues, also with a 5-kb band). In contrast, no ICA69 transcripts were detectable in rat spleen, thymus, bowel, lymph nodes, and salivary gland (not shown). The heterogeneity of mRNA size among tissues may be caused by an alternative splicing ofthe ICAI gene. As shown in Fig. 4 , the 2-kb ICAI transcript was detected in total RNA from human insulinoma and from a variety of endocrine cell lines, such as a human islet carcinoid cell line (BON-1), a hamster insulin-producing cell line (HIT), and three rodent islet cell lines, namely the rat RIN 1046-38 insulinoma cell line, the mouse f3TC-1 (producing primarily insulin, but also some glucagon, and which shows a transcript after longer exposure than shown in Fig. 4) , and the mouse aTC-6 (glucagon-C rc Figure 4 . producing clonal line). No ICAI transcripts were detected in total RNA from three human nonislet cell lines, namely HepG2-hepatoma, HeLa-cells, and JEG-choriocarcinoma (Fig. 4) .
Immunoblotting. Western blots of cell line extracts (RIN 1046-38, BON-l ) and brain tissue homogenate revealed a specific band of 69 kD after incubation with rabbit antibodies raised to the COOH terminus of ICA69 and an internal polypeptide. Fig. 5 illustrates that rabbit antiserum (rabbit number 1) raised against the COOH terminus of the molecule specifically reacted. with a protein of 69 kD in RIN 1046-38 and BON-1 (visible after longer exposure than shown in Fig. 5 ) total cell homogenate, but not with HeLa cell line homogenate. The specific 69-kD band disappears after absorption with the polypeptide against which specific antibodies were produced. The control serum from the same rabbit before the polypeptide immunization does not show any 69-kD reactivity. The same specific 69-kD reactivity was also detectable in rat brain total homogenate (not shown), and also using hyperimmune sera generated to an internal polypeptide as well as antiserum produced against the whole ICA69 molecule (see Methods). Since the deduced amino acid sequence ofICA69 is 483 residues with an estimated relative molecular mass of 54,600, the difference between the Western blot size ofthe protein fractionated in the SDS-PAGE and the estimated size based on the deduced amino acid sequence is likely caused by an aberrant migration of the RIN and the brain tissue proteins in SDS-PAGE as a result of detergent solubilization, as previously observed for a brain protein of approximately the same sequence deduced molecular mass and a similarly discrepant migration on SDS-PAGE (62, 63) .
Reactivity ofrecombinant ICA69 with serum offirst degree relatives ofIDDM patients on Western blotting. To determine whether sera from prediabetic subjects reacted with the recombinant ICA69 fusion protein, and then with the purified ICA69 recombinant molecule, further testing of Western blots was 1-2 (a) , samples from the same rabbit (rabbit number 1) before (Pre-J) and after (Post-i) the immunization with the deduced COOH terminus polypeptide of ICA69 (see Methods). Lanes 3-12, serum samples from 10 healthy individuals. In b, sera from seven prediabetics (PDM-l to 7), from two cytoplasmic islet cell antibody+/insulin autoantibody+ relatives who have not developed diabetes (+ / +), from one cytoplasmic islet cell antibody+ /insulin #utoantibody negative (+ / -) and two additional human control sera (C-I 1, C-12 ). Immunoblots showing reactivity of preclinical IDDM relatives cytoplasmic islet cell antibody-positive serum samples (PDM) with Ni-NTA-agarose purified recombinant (His)6-ICA69 (c and d). The purified ICA69 was separated by a 10% SDS-PAGE, and probed with sera from relatives of IDDM patients, and from controls (at 1:100 dilution). Lanes 1, 2, and 5 (c) and lanes 3 and 6 (d) show reactivity of sera from relatives of IDDM patients followed to the overt disease (PDM) with the 69-kD band. Cytoplasmic islet cell antibody/insulin autoantibodies (+/ + and -/+), serum samples from relatives of IDDM patients that have not developed the disease, show also reactivity with ICA69. Note the absence of detectable reactivity with control sera (lanes 6-12 in c; lanes 4 and 7-12 in d). All the sera from both prediabetics and controls used in the preliminary MBP/PM 1/3 clone fusion protein Western blot assay gave consistent results using the affinity-purified recombinant ICA69 as source of antigen for performing Western blots (some of the same serum samples, used in the immunoblots in a and b, are indicated with the same label in the two sets of immunoblots [ Fig. 6, a, b, c and d] ). Rabbit hyperimmune sera produced against the whole ICA69 and the COOH terminus of the molecule specifically reacted also with the Ni-NTA-agarose purified (His)6-ICA69 (not shown). Positions of molecular mass markers (Mr X 10-'), and -105 kD bands are indicated at right and left edges. The gels were exposed for 6-12 h.
performed. We first assessed whether antiserum raised against the COOH terminus and the whole ICA69 molecule, as well as the three sera from prediabetics previously reacting with the Xgtl IPTG-induced PM 1 / 1 insert, could react on a Western blot with the PM 1 /3 clone expressed as a fusion protein with maltose binding protein. The rabbit hyperimmune serum and 6 out of 10 sera from relatives with IDDM specifically reacted with a -105 kD band (Fig. 6, a and b) which corresponds to the SDS-PAGE migration ofthe whole fusion protein, whereas none of the 12 control sera reacted significantly (quantitating the sera reactivity to the -105 kD band by scanning densitometry).
Sera from first degree relatives from patients with insulindependent diabetes mellitus demonstrated specific binding to the affinity purified recombinant ICA69 on Western blotting (Fig. 6, c and d, and Fig. 7 ). Serum samples from 23 relatives of IDDM patients who were initially found to be ICA positive and then followed to the clinical onset ofthe disease (Pre-DM; Fig.  7) , 70 ICA69 islet immunohystochemistry. Staining of formalinfixed sections of rat pancreas with antibodies raised to the human recombinant ICA69 revealed selective cell reactivity (Fig. 8) . In islets double immuno-enzymatically labeled with a polyclonal antibody to ICA69 and with mAbs to glucagon or somatostatin, antibodies to ICA69 reacted with the cell core (Fig. 8 a) but not with either glucagon or somatostatin containing cells (Fig. 8, b and c) .
Chromosome localization ofIca-i, the mouse homologue, to chromosome 6. Linkage data summarized in Fig. 9 Fig. 9 . Though a polymorphism between NOD and NON exists for the Ica-I gene, and segregation of the NOD-derived Ica-i allele was not significantly associated with diabetes in either the backcross or the F2 generation (P > 0.05 by chi square analysis), indicating that it was not closely linked to a locus at the proximal end of chromosome 6 conferring susceptibility to insulin dependent diabetes (Idd gene) of NOD mice.
In the human, MET has been mapped to chromosome 7q2l-7q3 1 (65) . The localization of the mouse Ica-] gene within 6 cM ofthe Met protooncogene on chromosome 6, suggests that the human ICAI gene may be found close to the MET protooncogene protein-tyrosine kinase locus in a conserved region around 7q3 1.
Discussion
Recent findings have indicated that the range of autoantigens related to type I diabetes is more diverse than was originally thought. Sera from IDDM patients, as well as from stiff-man syndrome patients, appear to recognize one or both forms of the neuroendocrine-associated enzyme GAD (6, 66), namely GAD 65 (67) , and GAD 67 (68) , and one portion of the antibody response to islet cells, termed "restricted ICA," has been reported to recognize GAD (69, 70) . In the present study, we have cloned, sequenced, and characterized a novel 69-kD diabetes-related autoantigen.
In an attempt to identify molecular targets for antiislet autoimmunity in IDDM, we have used sera from preclinical IDDM subjects as probe to isolate cDNA clones from a human islet Xgtl 1 expression library. We have obtained a cDNA ofa novel protein that codes for a full-length amino acid sequence 54.6 kD with an apparent mobility of 69 type I diabetes. The fact that ICA69 mRNA is detected mostly in endocrine cell lines of islet cell origin, and that ICA69 mRNA is also detected in brain, thyroid and heart, but not skeletal muscle, suggests that ICA69 may be in fact related to the neuroendocrine system. A 2-kb mRNA band is visible in total RNA a glucagon producing cell line, namely aTC-6, whereas no staining is visible on normal rat glucagon containing cells detecting by immunohystochemistry.
The putative polypeptide encoded by the longest open reading frame of ICA69 clones has a molecular mass of 54,600 D. On Western blots, immunoreactive ICA69 has a molecular mass of 69 kD suggesting aberrant migration on SDS-PAGE. A molecular mass discrepancy between that calculated from the deduced amino acid sequence and that measured by SDS-PAGE, has been reported in the cloning of a number of proteins (62, 63, (72) (73) (74) . These proteins have highly charged regions that appear to be related to retarded SDS-PAGE gel migration, resulting thus in an overestimation of the true molecular mass. Our protein has several strongly charged regions, such as the segment of the molecule between residues 307 and 320. The fact that cDNA encoding the full length of the molecule produces a 69-kD protein when expressed in bacteria whose molecular mass is higher than the one inferred by the relative molecular mass of the deduced sequence (54.6 kD), supports aberrant gel migration as the likely cause of the relative molecular mass disparity.
Environmental factors are potential triggers of autoimmunity in type I diabetes ( 13) . There is evidence in animal models of IDDM such as BB rats that the elimination of cow milk proteins from the diet significantly reduces the incidence ofthe clinical onset of diabetes in these animals (75) . Sera from patients with type I diabetes as well as BB rats are reported to have high titer of IgG anti-BSA antibodies (but not of antibodies to other milk proteins) or IgG anti-ABBOS (a region of the BSA molecule extending from 152 to 158 amino acid residues) antibodies (13) (14) (15) The recombination frequencies between linked loci are expressed in cM±SEM (shown at the left) and were estimated using a weighted average for backcross and F2 data. Multipoint linkage map constructed using MAPMAKER 1.9 (64) gave maximum likelihood estimates for the best three gene orders as follows: order 1, Ica-I-D6MitJ-D6Rck2-Met log likelihood -79.10; order 2, D6Rek2-MetIca-i-D6MitJ4 log likelihood -82.85; and order 3, D6Rck2-MetD6Mitilca-l log likelihood -86.88. *Recombination frequency estimated from F2 data only.
with y-interferon-induced RIN 69-kD protein or with islet proteins with a similar mobility (60-70 kD), respectively (13) .
It is of interest that our 69-kD molecule shares two short regions of similarity with bovine serum albumin (not with human serum albumin precursor). These two antigenic determinants perhaps could play a role in the induction of cow milkinduced autoimmunity based upon the hypothesis ofpathogenesis related to molecular mimicry, or may be simply a cause of a cross-reactivity with anti-ICA69 antibodies and with anti-BSA antibodies. To prove one of these two hypotheses, further studies are required. We have just learned that a partial peptide sequence available from a p69 BSA-related molecule studied by Dosch and co-workers is identical to amino acids 262 to 325 of ICA69 (H.-M. Dosch, personal communication).
Our study shows that first degree relatives of patients with IDDM who developed the disease carry antibodies reacting with ICA69. Antibodies to ICA69 are detected also in relatives who have not yet developed the disease. Such antibodies are found in 43% of the serum samples from preclinical IDDM relatives assayed so far, and we believe that with the optimization of a more sensitive assay (such as a radioassay or an ELISA), the percentage of reactivity with ICA69 among IDDM relatives will increase.
Detecting by Western blotting, the percentage of anti-ICA69 reactivity among sera from relatives of IDDM patients that developed the disease and in from ICA+/IAA+ group appears to be higher than the ICA+/IAA-group (25%) (Fig.  7) , seemingly because all the anti-ICA69 negative sera from ICA+/IAA-relatives assayed thus far, show a /3 cell-selective ICA pattern (termed "restricted"), that includes recognition of GAD, which is associated with the lack of progression to overt diabetes (69, 70) . Therefore, the low percentage of anti-ICA69 positive sera in the ICA+/IAA-group as compared to the other groups appears to be related to the fact that most of the ICA+/IAA-IDDM serum samples from IDDM relatives assayed so far are restricted ICA and rarely progress to the overt IDDM. In light of these observations, we believe that with the combination of different assays for the detection of autoantibodies in IDDM, such as anti-IAA, anti-GAD, anti-ICA69, and in the future against other islet autoantigens, combinatorial algorithms for improving the prediction of type I diabetes will be designed.
The identification, the characterization of the molecular structure and the availability of the ICA69 molecule will help to add this autoantigen to a battery of markers for the prediction of diabetes risk, and will enhance our understanding of islet biochemistry. A family of islet antigen specific therapies are considered for the suppression of insulin-dependent diabetes; e.g., oral tolerance to insulin (76 
